Merus Labs International (MSLI) Receiving Somewhat Favorable News Coverage, Report Shows

News stories about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merus Labs International earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Merus Labs International (NASDAQ MSLI) remained flat at $1.30 on Monday. 1,428 shares of the company were exchanged. The stock has a 50 day moving average price of $1.20 and a 200-day moving average price of $0.94. The company’s market cap is $152.56 million. Merus Labs International has a 1-year low of $0.70 and a 1-year high of $1.33.

Several research analysts recently commented on the company. Zacks Investment Research raised Merus Labs International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Canaccord Genuity cut Merus Labs International to a “hold” rating and set a $1.65 price target for the company. in a research report on Thursday, May 11th. Seven equities research analysts have rated the stock with a hold rating, Merus Labs International currently has a consensus rating of “Hold” and a consensus target price of $1.35.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2722774/merus-labs-international-msli-receiving-somewhat-favorable-news-coverage-report-shows.html.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Insider Buying and Selling by Quarter for Merus Labs International (NASDAQ:MSLI)

Receive News & Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.